title: Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).
authors.affiliation: Division of Immunology, Netherlands Cancer Institute (NKI-AVL) , Amsterdam.
authors.forename: Sander
authors.initials: S
authors.lastname: Kelderman
authors.forename: Monique K
authors.initials: MK
authors.lastname: van der Kooij
authors.forename: Alfons J M
authors.initials: AJ
authors.lastname: van den Eertwegh
authors.forename: Patricia M M B
authors.initials: PM
authors.lastname: Soetekouw
authors.forename: Rob L H
authors.initials: RL
authors.lastname: Jansen
authors.forename: Rob R H
authors.initials: RR
authors.lastname: van den Brom
authors.forename: Geke A P
authors.initials: GA
authors.lastname: Hospers
authors.forename: John B A G
authors.initials: JB
authors.lastname: Haanen
authors.forename: Ellen
authors.initials: E
authors.lastname: Kapiteijn
authors.forename: Christian U
authors.initials: CU
authors.lastname: Blank
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D009367:Neoplasm Staging; D009426:Netherlands; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D014604:Uveal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D000098943:Uveal Melanoma
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab